We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





NEXTGENPCR Endpoint Thermocycler Decreases PCR Amplification Time for SARS-CoV-2 to Eight Minutes

By LabMedica International staff writers
Posted on 06 Apr 2020
Molecular Biology Systems, B.V. More...
(Goes, The Netherlands), a biotechnology company, has developed a method using its NEXTGENPCR endpoint thermocycler and consumables that decreases PCR amplification time for SARS-CoV-2 to eight minutes. Combined with smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, a qualitative protocol was generated that could readily detect SARS-CoV-2 control DNA, with equivalent sensitivity. A single unit, the size of a shoebox, could perform a hundred and eighty (180) amplification runs a day, an almost 10-fold increase over the current US Centers for Disease Control (CDC) recommended instrumentation. The detection of amplified product can be done with widely-available blue light gel document systems.

The NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results. Since the NEXTGENPCR accepts both 96 and 384-well reaction plates, the company tested both versions to increase throughput. By utilizing 384-well plates, the machine successfully processed four times as many samples without a loss in performance. The 384-well reaction chambers only require 25% of the reaction volume which would lower the supply burden placed on laboratories following the current CDC protocol. The company is now collaborating with testing laboratories in the US and the Netherlands to transfer and validate the method.

“We sought to decrease what we identified as the longest step in the current testing scheme, amplification. We started with the CDC assay because it is well characterized and has been readily available,” said Gert de Vos, CEO and founder of Molecular Biology Systems. “This protocol produces a simple yes/no answer — so a single machine, is capable of running 24/7, with eight-minute runs may provide a scalable screening solution analyzing 22,860 samples per day.”

Related Links:
Molecular Biology Systems, B.V.


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The screening algorithm incorporates two plasma biomarkers: amyloid-beta ratio and p-tau217, which together help indicate brain amyloid burden (Image Credit: Shutterstock)

Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening

Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.